Article

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer

2023-09-23

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes classified as classical/progenitor and basal-like/squamous. We hypothesized that integrative transcriptomic and metabolomic approaches can identify candidate genes whose inactivation contributes to the development of the aggressive basal-like/squamous subtype. Using our integrated approach, we identified endosome-ly...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 32b6a471-8f4a-5e76-be32-b9c99215b27d
DOI: 10.1101/2023.09.23.558894

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancerDOI 10.1101/2023.09.23.558894Read

ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancerSemantic proximity Read

LMO3 is a suppressor of the basal-like/squamous PDAC subtype and reduces disease aggressiveness of pancreatic cancer through glycerol 3-phosphate metabolismSemantic proximity Read

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)Semantic proximity Read

ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancerSemantic proximity Read

Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma ClassificationSemantic proximity Read

Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroupsSemantic proximity Read

ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancerSemantic proximity Read

Subtype specific metabolic vulnerabilities in pancreatic cancerSemantic proximity Read

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read

Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.Semantic proximity Read

Mitophagy-mediated molecular subtypes depict the hallmarks of the tumour metabolism and guide precision chemotherapy in pancreatic adenocarcinomaSemantic proximity Read

Exploring the metabolic landscape of pancreatic ductal adenocarcinoma cells using genome-scale metabolic modelingSemantic proximity Read